Enhanced in vitro transcytosis of simian immunodeficiency virus mediated by vaccine-induced antibody predicts transmitted/founder strain number after rectal challenge

Journal of Infectious Diseases

Volumn 211, Issue 1, 2015, Pages 45-52

  Gupta, Sandeep ^a   Pegu, Poonam ^b   Venzon, David J ^c   Gach, Johannes S ^a   Ma, Zhong Min ^d   Landucci, Gary ^a   Miller, Christopher J ^d,e   Franchini, Genoveffa ^b   Forthal, Donald N ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Animal Models and Retroviral Vaccine Section   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d Center for Comparative Medicine   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

antibody; Fc neonatal receptor; SIV; transcytosis; vaccine

Indexed keywords

FC NEONATAL RECEPTOR; FC RECEPTOR; GLYCOPROTEIN GP 120; IMMUNOGLOBULIN G ANTIBODY; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; UNCLASSIFIED DRUG; ANTIBODY; FC RECEPTOR, NEONATAL; HLA ANTIGEN CLASS 1; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APICAL MEMBRANE; ARTICLE; BASOLATERAL MEMBRANE; CONTROLLED STUDY; EPITHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; NONHUMAN; PH; RECTUM MUCOSA; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; TRANSCYTOSIS; VIRUS INFECTIVITY; VIRUS STRAIN; VIRUS TRANSMISSION; ANIMAL; ENDOMETRIUM TUMOR; FEMALE; IMMUNOLOGY; MALE; RECTUM; TUMOR CELL LINE; VIROLOGY;

ANIMALS; ANTIBODIES; CELL LINE, TUMOR; ENDOMETRIAL NEOPLASMS; EPITHELIAL CELLS; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MACACA MULATTA; MALE; RECEPTORS, FC; RECTUM; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; TRANSCYTOSIS; VIRAL VACCINES;

EID: 84922424248     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu300     Document Type: Article

References (21)

1. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209-20
2. Pitisuttithum P, Gilbert P, Gurwith M, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006; 194:1661-71
3. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005; 191:654-65
4. Pegu P, Vaccari M, Gordon S, et al. Antibodies with high avidity to the gp120 envelope protein in protection from simian immunoDeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial. J Virol 2013; 87:1708-19
5. Gupta S, Gach JS, Becerra JC, et al. The neonatal Fc receptor (FcRn) enhances human immunoDeficiency virus type 1 (HIV-1) transcytosis across epithelial cells. PLoS Pathog 2013; 9:e1003776
6. Kuo TT, Baker K, YoshiDa M, et al. Neonatal Fc receptor: from immunity to therapeutics. J Clin Immunol 2010; 30:777-89
7. Raghavan M, Gastinel LN, Bjorkman PJ. The class I major histocompatibility complex related Fc receptor shows pH-DepenDent stability differences correlating with immunoglobulin binding and release. Biochemistry 1993; 32:8654-60
8. Patton DL, Cosgrove Sweeney YT, Rabe LK, Hillier SL. Rectal applications of nonoxynol-9 cause tissue disruption in a monkey moDel. Sex Transm Dis 2002; 29:581-7
9. Keele BF, Li H, Learn GH, et al. Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med 2009; 206:1117-34
10. Hornby PJ, Cooper PR, Kliwinski C, et al. Human and non-human primate intestinal FcRn expression and immunoglobulin G transcytosis. Pharm Res 2014; 31:908-22
11. Shah U, Dickinson BL, Blumberg RS, Simister NE, Lencer WI, Walker WA. Distribution of the IgG Fc receptor, FcRn, in the human fetal intestine. Pediatr Res 2003; 53:295-301
12. YoshiDa M, Claypool SM, Wagner JS, et al. Human neonatal Fc receptor mediates transport of IgG into luminal secretions for Delivery of antigens to mucosal Dendritic cells. Immunity 2004; 20:769-83
13. Paveglio S, Puddington L, Rafti E, Matson AP. FcRn-mediated intestinal absorption of IgG anti-IgE/IgE immune complexes in mice. Clin Exp Allergy 2012; 42:1791-800
14. Fox CA, Meldrum SJ, Watson BW. Continuous measurement by radiotelemetry of vaginal pH during human coitus. J Reprod Fertil 1973; 33:69-75
15. Wright PF, Kozlowski PA, Rybczyk GK, et al. Detection of mucosal antibodies in HIV type 1-infected individuals. AIDS Res Hum Retroviruses 2002; 18:1291-300
16. Mestecky J, Jackson S, Moldoveanu Z, et al. Paucity of antigen-specific IgA responses in sera and external secretions of HIV-type 1-infected individuals. AIDS Res Hum Retroviruses 2004; 20:972-88
17. Gorlani A, Forthal DN. Antibody-DepenDent enhancement and the risk of HIV infection. Curr HIV Res 2013; 11:421-6
18. Forthal DN, Gabriel EE, Wang A, Landucci G, Phan TB. Association of Fcgamma receptor IIIa genotype with the rate of HIV infection after gp120 vaccination. Blood 2012; 120:2836-42
19. Brouwer KC, Lal RB, Mirel LB, et al. Polymorphism of Fc receptor IIa for IgG in infants is associated with susceptibility to perinatal HIV-1 infection. AIDS 2004; 18:1187-94
20. Onyango-Makumbi C, Omer SB, Mubiru M, et al. Safety and efficacy of HIV hyperimmune globulin for prevention of mother-to-child HIV transmission in HIV-1-infected pregnant women and their infants in Kampala, UganDa (HIVIGLOB/NVP STUDY). J Acquir Immune Defic Syndr 2011; 58:399-407
21. Burton DR, Hessell AJ, Keele BF, et al. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc Natl Acad Sci U S A 2011; 108:11181-6